Ann: Results of LCT Parkinsons trial require further analysis, page-93

First 93 Last

Share
Profile

Follow
MarketingMan

5,728 Posts.

3318

10/11/17

18:35

Post #: 28693702
Share

Originally posted by Borogrove ↑

THIS!
Even with poor results it was sloppy management and execution. The data and graphs they presented made it seem like everything got worse when in reality it was just not sig dif to the placebo.

If it was packaged as this for example;
"Every participant showed an improvement in Parkinsonian symptoms after 26 weeks. Unfortunately this was not significantly different to the placebo group. Out of the 18 participants with the NTcell treatment X performed better and X performed worse. X number were significantly better than the placebo and X number were significantly worse. The study has been unblinded but further data will be obtained on these cohorts up to 52 weeks. No adverse affects occurred. Further data analysis will look further into these following points -X,Y,Z. A follow up report can be expected on Xth of November"

Such a statement would be entirely valid and may have saved a few cents on the SP. I really think that the TH should have been held till Monday till they could properly disseminate results and present them. Anything positive that comes out now will be flat imo. Could have packaged a new direction in too, who the f**K knows if this has different effects at different progression points. If it affected longer Parkinson's sufferers better perhaps it could have different applications or even be valid to prevent dementia and Alzheimer's arising from PD. Given the amateurish delivery I must assume that they have nothing unless they are deliberately trying to tank their SP on bad news, the only alternative is great incompetence.

As pointed out before they should have had a worse and better in the graph at the very least as I am sure some would have misinterpreted it. Hope they get grilled at the AGM. Not blaming them for the bad results, the delivery was awful though.

For me selling out at this price I actually not think the results are near as as bad as they are now made out to be. If this is the case though what is more concerning to me is that the company is incapable of conveying this.

(On my phone as always and this is a longer post so sorry for any typos)

Expand

I entirely agree with you. These guys are lab rats not business people.
Their explanation was (words to the effect) "We want to be entirely transparent to our share holders; as soon as we have the numbers we let the market know" - but gee they could have packaged the delivery better.

I am a little worried that they saw the results and went into a mental decline "That's it, we're f**ked; may as well face the music" and then penned a negative market release guaranteed to deliver a death blow.

Get back in the lab guys and do your thing! You're almost there!
IMO
DYOR!!

LCT Price at posting: 4.0¢ Sentiment: Buy Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

ARN

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

RCE

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

There are more pages in this discussion • 71 more messages in this thread...

First 93 Last

Add 1AI (ASX) to my watchlist

(20min delay)
Last 0.9¢		Change 0.000(0.00%)		Mkt cap ! $15.18M

Open	High	Low	Value	Volume
0.9¢	0.9¢	0.9¢	$386	42.91K

Buyers (Bids)

No.	Vol.	Price($)
5	163615	0.9¢

Sellers (Offers)

Price($)	Vol.	No.
1.0¢	633746	2

View Market Depth

No.	Vol.	Price($)
5	163615	0.009
12	5396180	0.008
8	6360009	0.007
6	2493750	0.006
4	2300000	0.005

Price($)	Vol.	No.
0.010	633746	2
0.011	1281697	10
0.012	2385405	7
0.013	894768	4
0.014	126665	2

Last trade - 10.09am 15/07/2024 (20 minute delay)

1AI (ASX) Chart

Ann: Results of LCT Parkinsons trial require further analysis, page-93

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Results of LCT Parkinsons trial require further analysis, page-93

Top Stories

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News